{
    "meeting_annotations": [
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "00:01-00:04",
            "transcript": "Okay, so let's kick this off. Welcome, everyone.",
            "speaking_duration": 3,
            "self_expression": "welcoming, professional",
            "others_expression": "attentive, neutral",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "None"
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "00:04-00:15",
            "transcript": "The main goal for today is to brainstorm some initial concepts for the cellular regeneration project. We want to leave this meeting with at least three distinct pathways to explore.",
            "speaking_duration": 11,
            "self_expression": "focused, leading",
            "others_expression": "nodding, engaged",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "None"
        },
        {
            "speaker": "Dr. Kenji Tanaka",
            "timestamp": "00:15-00:28",
            "transcript": "Great. I was reviewing the preliminary data on transcription factor cocktails. I think there's a strong case to be made for focusing on a Yamanaka-factor-adjacent approach, but with a modified delivery system.",
            "speaking_duration": 13,
            "self_expression": "confident, prepared, enthusiastic",
            "others_expression": "nodding, intrigued, engaged",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "None"
        },
        {
            "speaker": "Dr. Lena Petrova",
            "timestamp": "00:28-00:41",
            "transcript": "That's interesting, Kenji. My concern with that is the off-target effects we've seen with viral vectors. Perhaps we should consider a non-integrating method, maybe something with synthetic mRNA from the start?",
            "speaking_duration": 13,
            "self_expression": "thoughtful, constructive, curious",
            "others_expression": "engaged, considering",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "Dr. Carter is visibly taking notes, indicating active listening and processing."
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "00:41-00:43",
            "transcript": "Good points. Let me share my screen.",
            "speaking_duration": 2,
            "self_expression": "facilitating, organized",
            "others_expression": "attentive, watching",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "Dr. Thorne initiates a screen share, bringing up a blank white document application to take shared notes.",
            "other": "None"
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "00:43-00:55",
            "transcript": "I'll capture these ideas as we go. So, Pathway 1: Modified Yamanaka Factors. And under that, Kenji suggests a novel delivery system, while Lena raises the point of using synthetic mRNA to avoid integration.",
            "speaking_duration": 12,
            "self_expression": "organizing, clarifying",
            "others_expression": "engaged, watching screen, nodding",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "The screen shows a document where Dr. Thorne types out the first proposed pathway and its two competing sub-points, attributing each to the person who suggested it. This serves to validate contributions and create a shared record.",
            "other": "None"
        },
        {
            "speaker": "Dr. Ben Carter",
            "timestamp": "00:55-01:10",
            "transcript": "What if we sidestep the reprogramming factors entirely for a moment? My work in developmental biology suggests we could leverage endogenous repair mechanisms by targeting specific signaling pathways, like Hippo or Wnt, with small molecules.",
            "speaking_duration": 15,
            "self_expression": "confident, enthusiastic",
            "others_expression": "intrigued, surprised, leaning in",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "The screen content remains unchanged during this segment, showing the notes on Pathway 1.",
            "other": "This is a moment of divergent thinking, introducing a completely new concept to the discussion."
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "01:10-01:12",
            "transcript": "Okay, I like that. A completely different angle.",
            "speaking_duration": 2,
            "self_expression": "encouraging, positive",
            "others_expression": "nodding in agreement",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "The screen content remains unchanged.",
            "other": "None"
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "01:12-01:20",
            "transcript": "Let's call that Pathway 2: Small Molecule Activation of Endogenous Repair. We can specify Hippo and Wnt pathways.",
            "speaking_duration": 8,
            "self_expression": "organizing, synthesizing",
            "others_expression": "watching the screen, engaged",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "Dr. Thorne adds a new heading for 'Pathway 2' to the shared document, summarizing Dr. Carter's idea and adding the specific examples he mentioned. This action validates and integrates the new idea into the group's plan.",
            "other": "None"
        },
        {
            "speaker": "Dr. Kenji Tanaka",
            "timestamp": "01:20-01:35",
            "transcript": "That's a great idea, Ben. We could even combine the approaches. Use a small molecule cocktail to prime the tissue, making it more receptive to a subsequent, much lower dose of reprogramming factors. It could mitigate the risks Lena mentioned.",
            "speaking_duration": 15,
            "self_expression": "collaborative, excited",
            "others_expression": "smiling, nodding enthusiastically",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "The screen shows the two documented pathways. No changes are made during this segment.",
            "other": "This is a clear example of idea synthesis, combining two previously separate concepts into a novel third option."
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "01:35-01:45",
            "transcript": "Excellent, Kenji. So, our third pathway is a hybrid approach. Pathway 3: Priming with Small Molecules followed by Low-Dose Reprogramming. This is fantastic. We have our three pathways.",
            "speaking_duration": 10,
            "self_expression": "pleased, summarizing, decisive",
            "others_expression": "smiling, nodding, showing consensus",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "Dr. Thorne types the third pathway into the shared document, summarizing the synthesized idea. The document now clearly displays the three distinct concepts the team generated during the meeting.",
            "other": "The team successfully and efficiently achieved the meeting's stated goal."
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "01:45-01:52",
            "transcript": "Okay, great work, everyone. For next steps, let's each take a pathway to flesh out for our meeting next week.",
            "speaking_duration": 7,
            "self_expression": "conclusive, forward-looking",
            "others_expression": "attentive, ready for assignments",
            "interuption": "No",
            "screenshare": "Yes",
            "screenshare_content": "The screen shows the final list of three pathways. No changes are made.",
            "other": "The screen share is stopped at the end of this segment."
        },
        {
            "speaker": "Dr. Lena Petrova",
            "timestamp": "01:52-01:56",
            "transcript": "I can take the synthetic mRNA approach for Pathway 1.",
            "speaking_duration": 4,
            "self_expression": "proactive, willing",
            "others_expression": "nodding",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "None"
        },
        {
            "speaker": "Dr. Ben Carter",
            "timestamp": "01:56-01:59",
            "transcript": "I'll take Pathway 2 with the small molecules.",
            "speaking_duration": 3,
            "self_expression": "eager, clear",
            "others_expression": "nodding",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "None"
        },
        {
            "speaker": "Dr. Kenji Tanaka",
            "timestamp": "01:59-02:02",
            "transcript": "And I'm happy to explore the hybrid approach.",
            "speaking_duration": 3,
            "self_expression": "collaborative, agreeable",
            "others_expression": "nodding",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "None"
        },
        {
            "speaker": "Dr. Aris Thorne",
            "timestamp": "02:02-02:06",
            "transcript": "Perfect. That's settled then. I'll send out the notes. Talk to you all next week. Bye.",
            "speaking_duration": 4,
            "self_expression": "efficient, positive, concluding",
            "others_expression": "waving, smiling",
            "interuption": "No",
            "screenshare": "No",
            "screenshare_content": "None",
            "other": "None"
        }
    ]
}